Laura Sue Grosmaire,Martha Susan Hayden-Ledbetter,Jeffrey A. Ledbetter,Peter Armstrong Thompson,Sandy Alexander Simon,William Brady
申请号：
US13836103
公开号：
US10143748B2
申请日:
2013.03.15
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
